The City of Hope National Medical Center (COHNMC) has been at the forefront of medical and basic science research since it was established in 1918. A formal research program structure was initiated in 1951 and expanded rapidly in terms of staff, facilities, and institutional support. Major groups of investigators were recruited and merged into the Research Institute in molecular biology, immunology, and the neurosciences. By the late 1970s approximately 100 PhD level investigators were conducting a broad range of research programs. The COHNMC facility is located 20 miles northeast of Los Angeles, California. The campus is a 93- acre inpatient, outpatient, and research complex of 102 buildings dedicated to the prevention, diagnosis, and treatment of cancer.

Janet Yoon, MD received her medical degree from the Medical College of Ohio and then served as a pediatric resident at the Medical University of South Carolina. She moved to California to pursue a pediatric hematology/oncology fellowship at Children’s Hospital Los Angeles. Prior to joining City of Hope in August 2022, Dr. Yoon was at University of California Davis Medical Center then spent over a decade at University of California San Diego/Rady Children’s Hospital San Diego where she was a clinical professor and director of the pediatric solid tumor program.

At City of Hope, Dr. Yoon is a clinical professor who serves as the medical director of the pediatric musculoskeletal tumor program and section chief of pediatric solid tumors. She works closely with the adult sarcoma team to bring new and innovative clinical trials to the adolescent and young adult sarcoma population. As the leader of the pediatric clinical research program, she oversees the operations and conduct of clinical trials.

Dr. Yoon specializes in pediatric hematology/oncology because it allows her to build long-term relationships with her young patients and their caregivers. Inspired by their resilience and strength, she stays at the leading edge of her field so that she can introduce families to the latest therapies, specifically those that minimize harmful and long-lasting side effects.

Dr. Lindsey Murphy received her Bachelor’s degree in Biology and Applied Mathematics from Pepperdine University and then went on to receive her MD from the University of Nevada School of Medicine. She completed a pediatric residency at The University of Washington/Seattle Children’s Hospital follow by a fellowship in pediatric hematology and oncology at The University of Colorado/Children’s Hospital Colorado. She joined the faculty at City of Hope in 2023 where she serves as an Assistant professor in the Department of Pediatrics. She holds dual board certification in pediatrics and pediatric hematology/oncology. Her clinical and research interests are focused in relapsed and refractory pediatric leukemias. These research efforts include investigating potential new biomarkers for targeted therapies (including CAR T cell therapies) and translating those into clinical trials as novel therapeutic approaches for relapsed and refractory pediatric leukemia. She completed a Masters in Clinical Science at the University of Colorado which allowed her to gain additional experience with clinical trial design and conduct. She has gained extensive experience with early phase clinical trials in children with relapsed malignancies and serves as the site primary investigator for several early phase trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric leukemia.